Trial Profile

A Phase II Study of Radium-223 in Combination with Enzalutamide in Progressive Metastatic Castrate-Resistant Prostate Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enzalutamide (Primary) ; Radium 223 chloride (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions
Acronyms CTRIAL-IE

Most Recent Events

09 Dec 2021 Status changed from active, no longer recruiting to completed.
07 Jan 2020 Planned End Date changed from 1 Apr 2021 to 1 Dec 2022.
16 Feb 2019 Results of an updated analysis evaluating skeletal related events presented at the 2019 Genitourinary Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com